141 related articles for article (PubMed ID: 29345176)
61. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
[TBL] [Abstract][Full Text] [Related]
62. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
[TBL] [Abstract][Full Text] [Related]
63. Vascular endothelial growth factor-C modulates proliferation and chemoresistance in acute myeloid leukemic cells through an endothelin-1-dependent induction of cyclooxygenase-2.
Hua KT; Lee WJ; Yang SF; Chen CK; Hsiao M; Ku CC; Wei LH; Kuo ML; Chien MH
Biochim Biophys Acta; 2014 Feb; 1843(2):387-97. PubMed ID: 24184161
[TBL] [Abstract][Full Text] [Related]
64. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
65. Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.
Baumgarten P; Blank AE; Franz K; Hattingen E; Dunst M; Zeiner P; Hoffmann K; Bähr O; Mäder L; Goeppert B; Machein M; Seifert V; Steinbach JP; Plate KH; Harter PN; Mittelbronn M
Neuro Oncol; 2016 Feb; 18(2):173-83. PubMed ID: 26627848
[TBL] [Abstract][Full Text] [Related]
66. Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.
Wang X; Zhang L; Zhao F; Xu R; Jiang J; Zhang C; Liu H; Huang H
Ann Hematol; 2018 Aug; 97(8):1375-1389. PubMed ID: 29654398
[TBL] [Abstract][Full Text] [Related]
67. [Expression of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA in bone marrow of leukemia patients and its clinical significance].
Xu N; He QT; Lu Y; Han XM; Ma HJ; Zhang DX; Liu XW; Yuan XJ; Jia GR; Li J; Li Z; Li ZQ; Han HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1368-73. PubMed ID: 22169285
[TBL] [Abstract][Full Text] [Related]
68. Expression of GLI1 correlates with expression of lymphangiogenesis proteins, vascular endothelial growth factor C and vascular endothelial growth factor receptor 3, in colorectal cancer.
Hong KD; Lee Y; Kim BH; Lee SI; Moon HY
Am Surg; 2013 Feb; 79(2):198-204. PubMed ID: 23336661
[TBL] [Abstract][Full Text] [Related]
69. Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia.
Hou HA; Chou WC; Lin LI; Tang JL; Tseng MH; Huang CF; Yao M; Chen CY; Tsay W; Tien HF
Leuk Res; 2008 Jun; 32(6):904-12. PubMed ID: 17904634
[TBL] [Abstract][Full Text] [Related]
70. Prognostic factors in the myelodysplastic syndromes: a review.
Tricot G; Vlietinck R; Verwilghen RL
Scand J Haematol Suppl; 1986; 45():107-13. PubMed ID: 3515514
[No Abstract] [Full Text] [Related]
71. Diagnostic criteria for hypocellular acute leukemia: a clinical entity distinct from overt acute leukemia and myelodysplastic syndrome.
Nagai K; Kohno T; Chen YX; Tsushima H; Mori H; Nakamura H; Jinnai I; Matsuo T; Kuriyama K; Tomonaga M; Bennett JM
Leuk Res; 1996 Jul; 20(7):563-74. PubMed ID: 8795690
[TBL] [Abstract][Full Text] [Related]
72. Low miR-192 expression predicts poor prognosis in pediatric acute myeloid leukemia.
Tian C; Zhang L; Li X; Zhang Y; Li J; Chen L
Cancer Biomark; 2018; 22(2):209-215. PubMed ID: 29689705
[TBL] [Abstract][Full Text] [Related]
73. Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome.
Li S; Yin CC; Medeiros LJ; Bueso-Ramos C; Lu G; Lin P
Am J Clin Pathol; 2012 Jul; 138(1):146-52. PubMed ID: 22706870
[TBL] [Abstract][Full Text] [Related]
74. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
[TBL] [Abstract][Full Text] [Related]
75. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
76. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
77. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.
Bacher U; Kern W; Alpermann T; Schnittger S; Kohlmann A; Klein HU; Dugas M; Haferlach C; Haferlach T
Leukemia; 2011 Aug; 25(8):1361-4. PubMed ID: 21494258
[No Abstract] [Full Text] [Related]
78. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category.
Weinberg OK; Hasserjian RP; Li B; Pozdnyakova O
J Clin Pathol; 2017 Feb; 70(2):109-115. PubMed ID: 27387988
[TBL] [Abstract][Full Text] [Related]
79. CD147 and VEGF co-expression predicts prognosis in patients with acute myeloid leukemia.
Fu J; Fu J; Chen X; Zhang Y; Gu H; Bai Y
Jpn J Clin Oncol; 2010 Nov; 40(11):1046-52. PubMed ID: 20558462
[TBL] [Abstract][Full Text] [Related]
80. Genetic alteration patterns and clinical outcomes of elderly and secondary acute myeloid leukemia.
Wang SY; Cheng WY; Mao YF; Zhu YM; Liu FJ; Ma TT; Shen Y
Hematol Oncol; 2019 Oct; 37(4):456-463. PubMed ID: 31348835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
